Eloxx Pharmaceuticals, a clinical-stage biopharmaceutical company, completed its acquisition of a minority stake in Zikani Therapeutics, an emerging company in the science of ribosome modulation, for $25m. “With the strength of our ELX-02 program for cystic fibrosis, this acquisition provides us with the opportunity to amplify the potential of our innovative science by developing a new class of therapies to treat diseases with limited to no treatment options under the stewardship of leaders with a proven ability to translate technology into treatments for patients,” Tomer Kariv, Eloxx Chairman.